These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 33947959)

  • 1. LRIG1 is a conserved EGFR regulator involved in melanoma development, survival and treatment resistance.
    Billing O; Holmgren Y; Nosek D; Hedman H; Hemmingsson O
    Oncogene; 2021 May; 40(21):3707-3718. PubMed ID: 33947959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LRIG1 acts as a critical regulator of melanoma cell invasion, migration, and vasculogenic mimicry upon hypoxia by regulating EGFR/ERK-triggered epithelial-mesenchymal transition.
    Li W; Zhou Y
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30487162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells.
    Zhang X; Song Q; Wei C; Qu J
    Cell Stress Chaperones; 2015 Jul; 20(4):631-41. PubMed ID: 25860915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of LRIG1, a Negative Regulator of EGFR, Is Dynamically Altered during Different Stages of Gastric Carcinogenesis.
    Yu S; Yang M; Lim KM; Cho Y; Kim H; Lee K; Jeong SH; Coffey RJ; Goldenring JR; Nam KT
    Am J Pathol; 2018 Dec; 188(12):2912-2923. PubMed ID: 30248341
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leucine-rich repeat and immunoglobulin domain-containing protein-1 (Lrig1) negative regulatory action toward ErbB receptor tyrosine kinases is opposed by leucine-rich repeat and immunoglobulin domain-containing protein 3 (Lrig3).
    Rafidi H; Mercado F; Astudillo M; Fry WH; Saldana M; Carraway KL; Sweeney C
    J Biol Chem; 2013 Jul; 288(30):21593-605. PubMed ID: 23723069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1.
    Yan R; Li K; Yuan DW; Wang HN; Zhang Y; Dang CX; Zhu K
    Int J Oncol; 2018 Dec; 53(6):2566-2578. PubMed ID: 30320337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The transmembrane protein LRIG1 triggers melanocytic tumor development following chemically induced skin carcinogenesis.
    Hoesl C; Fröhlich T; Posch C; Kneitz H; Goebeler M; Schneider MR; Dahlhoff M
    Mol Oncol; 2021 Aug; 15(8):2140-2155. PubMed ID: 33786987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity.
    Chang L; Shi R; Yang T; Li F; Li G; Guo Y; Lang B; Yang W; Zhuang Q; Xu H
    J Exp Clin Cancer Res; 2013 Dec; 32(1):101. PubMed ID: 24314030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRIG1 regulates cadherin-dependent contact inhibition directing epithelial homeostasis and pre-invasive squamous cell carcinoma development.
    Lu L; Teixeira VH; Yuan Z; Graham TA; Endesfelder D; Kolluri K; Al-Juffali N; Hamilton N; Nicholson AG; Falzon M; Kschischo M; Swanton C; Wright NA; Carroll B; Watt FM; George JP; Jensen KB; Giangreco A; Janes SM
    J Pathol; 2013 Mar; 229(4):608-20. PubMed ID: 23208928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Upregulation of LRIG1 suppresses malignant glioma cell growth by attenuating EGFR activity.
    Ye F; Gao Q; Xu T; Zeng L; Ou Y; Mao F; Wang H; He Y; Wang B; Yang Z; Guo D; Lei T
    J Neurooncol; 2009 Sep; 94(2):183-94. PubMed ID: 19300910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-suppressive effect of LRIG1, a negative regulator of ErbB, in non-small cell lung cancer harboring mutant EGFR.
    Torigoe H; Yamamoto H; Sakaguchi M; Youyi C; Namba K; Sato H; Shien K; Soh J; Suzawa K; Tomida S; Tsukuda K; Miyoshi S; Toyooka S
    Carcinogenesis; 2018 May; 39(5):719-727. PubMed ID: 29546323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulation of leucine-rich repeats and immunoglobulin-like domains 1 by microRNA-20a modulates gastric cancer multidrug resistance.
    Zhou L; Li X; Zhou F; Jin Z; Chen D; Wang P; Zhang S; Zhuge Y; Shang Y; Zou X
    Cancer Sci; 2018 Apr; 109(4):1044-1054. PubMed ID: 29450946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aryl Hydrocarbon Receptor Defect Attenuates Mitogen-Activated Signaling through Leucine-Rich Repeats and Immunoglobulin-like Domains 1 (LRIG1)-Dependent EGFR Degradation.
    Hsu HL; Chen HK; Tsai CH; Liao PL; Chan YJ; Lee YC; Lee CC; Li CH
    Int J Mol Sci; 2021 Sep; 22(18):. PubMed ID: 34576152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.
    Cheng SQ; Fan HY; Xu X; Gao WW; Lv SG; Ye MH; Wu MJ; Shen XL; Cheng ZJ; Zhu XG; Zhang Y
    J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):558-563. PubMed ID: 27465333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isoliquiritigenin suppresses human melanoma growth by targeting miR-301b/LRIG1 signaling.
    Xiang S; Chen H; Luo X; An B; Wu W; Cao S; Ruan S; Wang Z; Weng L; Zhu H; Liu Q
    J Exp Clin Cancer Res; 2018 Aug; 37(1):184. PubMed ID: 30081934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.
    Xie R; Yang H; Xiao Q; Mao F; Zhang S; Ye F; Wan F; Wang B; Lei T; Guo D
    Oncol Rep; 2013 Jan; 29(1):177-84. PubMed ID: 23124613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
    Qi XC; Xie DJ; Yan QF; Wang YR; Zhu YX; Qian C; Yang SX
    Biochem Biophys Res Commun; 2013 Aug; 437(4):565-72. PubMed ID: 23850692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma.
    Sun C; Wang L; Huang S; Heynen GJ; Prahallad A; Robert C; Haanen J; Blank C; Wesseling J; Willems SM; Zecchin D; Hobor S; Bajpe PK; Lieftink C; Mateus C; Vagner S; Grernrum W; Hofland I; Schlicker A; Wessels LF; Beijersbergen RL; Bardelli A; Di Nicolantonio F; Eggermont AM; Bernards R
    Nature; 2014 Apr; 508(7494):118-22. PubMed ID: 24670642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LRIG2 promotes the proliferation and cell cycle progression of glioblastoma cells in vitro and in vivo through enhancing PDGFRβ signaling.
    Xiao Q; Dong M; Cheng F; Mao F; Zong W; Wu K; Wang H; Xie R; Wang B; Lei T; Guo D
    Int J Oncol; 2018 Sep; 53(3):1069-1082. PubMed ID: 30015847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRIG1 enhances the radiosensitivity of radioresistant human glioblastoma U251 cells via attenuation of the EGFR/Akt signaling pathway.
    Yang JA; Liu BH; Shao LM; Guo ZT; Yang Q; Wu LQ; Ji BW; Zhu XN; Zhang SQ; Li CJ; Chen QX
    Int J Clin Exp Pathol; 2015; 8(4):3580-90. PubMed ID: 26097540
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.